Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India

被引：21

作者：

Bhatla, Neerja ^{[1
]}

Nene, Bhagwan M. ^{[2
]}

Joshi, Smita ^{[3
]}

Esmy, Pulikottil O. ^{[4
]}

Poli, Usha Rani Reddy ^{[5
]}

Joshi, Geeta ^{[6
]}

Verma, Yogesh ^{[7
]}

Zomawia, Eric ^{[8
]}

Pimple, Sharmila ^{[9
]}

Prabhu, Priya R. ^{[10
]}

Basu, Partha

Muwonge, Richard ^{[11
]}

Hingmire, Sanjay ^{[2
]}

Sauvaget, Catherine ^{[11
]}

Lucas, Eric ^{[11
]}

Pawlita, Michael ^{[12
]}

Gheit, Tarik ^{[13
]}

Jayant, Kasturi ^{[2
]}

Malvi, Sylla G. ^{[2
]}

Siddiqi, Maqsood ^{[14
]}

Michel, Angelika ^{[12
]}

Butt, Julia ^{[12
]}

Sankaran, Subha ^{[10
]}

Kannan, Thiraviam Pillai Rameshwari Ammal ^{[10
]}

Varghese, Rintu ^{[10
]}

Divate, Uma

Willhauck-Fleckenstein, Martina ^{[12
]}

Waterboer, Tim ^{[12
]}

Mueller, Martin ^{[12
]}

Sehr, Peter ^{[15
]}

Kriplani, Alka ^{[1
]}

Mishra, Gauravi ^{[9
]}

Jadhav, Radhika ^{[3
]}

Thorat, Ranjit ^{[2
]}

Tommasino, Massimo ^{[13
]}

Pillai, M. Radhakrishna ^{[10
]}

Sankaranarayanan, Rengaswamy ^{[11
]}

机构：

[1] All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi 110029, India

[2] Nargis Dutt Mem Canc Hosp, Tata Mem Ctr Rural Canc Project, Solapur 413401, Maharashtra, India

[3] Jehangir Hosp Premises, Jehangir Clin Dev Ctr, Pune 411001, Maharashtra, India

[4] Christian Fellowship Community Hlth Ctr, Ambillikai 624612, Tamil Nadu, India

[5] MNJ Inst Oncol & Reg Canc Ctr, Red Hills, Hyderabad 500004, Andhra Prades, India

[6] MP Shah Canc Hosp, GCRI, Civil Hosp Campus, Ahmadabad 380016, Gujarat, India

[7] Sikkim Manipal Univ, Sikkim Manipal Inst Med Sci, Sikkim 737101, Sikkim, India

[8] Civil Hosp, Aizawl 796001, Mizoram, India

[9] Tata Mem Hosp & Canc Res Inst, Tata Mem Ctr, Dept Prevent Oncol, Bombay 400012, Maharashtra, India

[10] Rajiv Gandhi Ctr Biotechnol, Thiruvananthapuram 695014, Kerala, India

[11] Int Agcy Res Canc, Sect Early Detect & Prevent, Screening Grp, 50 Cours Albert Thomas, F-69372 Lyon 08, France

[12] German Canc Res Ctr, Infect Inflammat & Canc Program, Neuenheimer Feld 242, D-69120 Heidelberg, Germany

[13] Int Agcy Res Canc, Sect Infect & Canc Biol, Lyon, France

[14] Canc Fdn India, Kolkata 700039, W Bengal, India

[15] European Mol Biol Lab, EMBL DKFZ Chem Biol Core Facil, D-69117 Heidelberg, Germany

来源：

PAPILLOMAVIRUS RESEARCH | 2018年 / 5卷

基金：

比尔及梅琳达.盖茨基金会;

关键词：

Human papillomavirus; Quadrivalent vaccine; Two doses; age; 15-18; years; Immunogenicity; Incident infections; Persistent infections;

D O I：

10.1016/j.pvr.2018.03.008

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Extending two-dose recommendations of HPV vaccine to girls between 15 and 18 years will reduce program cost and improve compliance. Immunogenicity and vaccine targeted HPV infection outcomes were compared between 1795 girls aged 15-18 years receiving two (1-180 days) and 1515 girls of same age receiving three (1-60-180 days) doses. Immunogenicity outcomes in 15-18 year old two-dose recipients were also compared with the 10-14 year old three-dose (N = 2833) and two-dose (N = 3184) recipients. The 15-18 year old two-dose recipients had non-inferior L1-binding antibody titres at seven months against vaccine-targeted HPV types compared to three-dose recipients at 15-18 years and three-dose recipients at 10-14 years of age. Neutralizing antibody titres at 18 months in 15-18 year old two-dose recipients were non-inferior to same age three-dose recipients for all except HPV 18. The titres were inferior to those in the 10-14 year old three-dose recipients for all targeted types. Frequency of incident infections from vaccine-targeted HPV types in the 15-18 year old two-dose recipients was similar to the three dose recipients. None of the girls receiving two or three doses had persistent infection from vaccine-targeted types. These findings support that two doses of HPV vaccine can be extended to girls aged 15-18 years.

引用

页码：163 / 171

页数：9

共 27 条

[1]

[Anonymous], 2017, Wkly Epidemiol Rec, V92, P241

[2]

[Anonymous], 2014, IMM VACC BIOL SUMM S

[3] Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women [J].

Bhatla, Neerja ;

Suri, Vanita ;

Basu, Partha ;

Shastri, Surendra ;

Datta, Sanjoy K. ;

Bi, Dan ;

Descamps, Dominique J. ;

Bock, Hans L. .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (01) :123-132

[4] Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women [J].

Block, Stan L. ;

Nolan, Terry ;

Sattler, Carlos ;

Barr, Eliav ;

Giacoletti, Katherine E. D. ;

Marchant, Colin D. ;

Castellsague, Xavier ;

Rusche, Steven A. ;

Lukac, Suzanne ;

Bryan, Janine T. ;

Cavanaugh, Paul F., Jr. ;

Reisinger, Keith S. .

PEDIATRICS, 2006, 118 (05) :2135-2145

[5]

Brady AM, 2017, FASEB J, V31

[6] In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection [J].

Day, Patricia M. ;

Kines, Rhonda C. ;

Thompson, Cynthia D. ;

Jagu, Subhashini ;

Roden, Richard B. ;

Lowy, Douglas R. ;

Schiller, John T. .

CELL HOST & MICROBE, 2010, 8 (03) :260-270

[7] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial [J].

Dillner, Joakim ;

Kjaer, Susanne K. ;

Wheeler, Cosette M. ;

Sigurdsson, Kristjan ;

Iversen, Ole-Erik ;

Hernandez-Avila, Mauricio ;

Perez, Gonzalo ;

Brown, Darron R. ;

Koutsky, Laura A. ;

Tay, Eng Hseon ;

Garcia, Patricia ;

Ault, Kevin A. ;

Garland, Suzanne M. ;

Leodolter, Sepp ;

Olsson, Sven-Eric ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Paavonen, Jorma ;

Lehtinen, Matti ;

Steben, Marc ;

Bosch, F. Xavier ;

Joura, Elmar A. ;

Majewski, Slawomir ;

Munoz, Nubia ;

Myers, Evan R. ;

Villa, Luisa L. ;

Taddeo, Frank J. ;

Roberts, Christine ;

Tadesse, Amha ;

Bryan, Janine T. ;

Maansson, Roger ;

Lu, Shuang ;

Vuocolo, Scott ;

Hesley, Teresa M. ;

Barr, Eliav ;

Haupt, Richard .

BRITISH MEDICAL JOURNAL, 2010, 341 :239

[8] Update on Vaccination Clinical Trials for HPV-Related Disease [J].

Erickson, Britt K. ;

Landers, Emily E. ;

Huh, Warner K. .

CLINICAL THERAPEUTICS, 2014, 36 (01) :8-16

[9]

*INT AG RES CANC, 2007, IARC MON EV CARC RIS, V90

[10] The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding [J].

Kines, Rhonda C. ;

Thompson, Cynthia D. ;

Lowy, Douglas R. ;

Schiller, John T. ;

Day, Patricia M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (48) :20458-20463

← 1 2 3 →